Pulmonary hypertension is a condition in which blood pressure inside the arteries of the lungs is abnormally high. It’s diagnosed when the mean pressure in the pulmonary arteries exceeds 20 mmHg, measured by threading a catheter into the right side of the heart. Unlike regular high blood pressure, which affects arteries throughout the body, pulmonary hypertension specifically strains the right side of the heart, which has to pump harder to push blood through narrowed or stiffened lung vessels.
What Happens Inside the Lungs
In healthy lungs, blood flows easily through a network of small arteries to pick up oxygen. In pulmonary hypertension, the walls of those arteries thicken and stiffen through a process called vascular remodeling. The cells lining the inside of the vessels malfunction, proliferating when they shouldn’t and resisting the normal signals that would tell them to stop growing. Smooth muscle cells in the artery walls shift from their usual role of contracting and relaxing into a mode where they multiply and migrate, further narrowing the passageway for blood.
This narrowing forces the right ventricle of the heart to work progressively harder. Over time, the right ventricle enlarges and weakens. The downstream consequence is that less oxygen-rich blood reaches the rest of the body, which explains why fatigue and breathlessness are hallmark symptoms.
The Five Types of Pulmonary Hypertension
The condition is classified into five groups based on its underlying cause, because treatment depends heavily on what’s driving the elevated pressure.
- Group 1: Pulmonary arterial hypertension (PAH). This is the form most people mean when they say “pulmonary hypertension” without qualification. It can be inherited, triggered by certain drugs (such as amphetamines or older appetite suppressants), or linked to conditions like connective tissue disease, HIV, congenital heart defects, or liver cirrhosis. In some cases, no cause is found at all. What unifies Group 1 is that the problem originates in the small pulmonary arteries themselves.
- Group 2: Left heart disease. The most common type overall. When the left side of the heart doesn’t pump efficiently or a heart valve leaks or narrows, pressure backs up into the lungs. The pulmonary arteries themselves may be relatively normal; the elevated pressure is a consequence of problems downstream.
- Group 3: Lung disease or chronic low oxygen. Conditions like COPD, interstitial lung disease, or even long-standing sleep apnea can raise pulmonary pressures. The pressure elevations tend to be milder than in other groups.
- Group 4: Chronic blood clots in the lungs (CTEPH). Old blood clots that never fully dissolve can block or narrow pulmonary arteries. This form is notable because it can sometimes be cured with surgery to remove the clot material, without needing a transplant.
- Group 5: Miscellaneous causes. A catch-all for conditions like sarcoidosis, certain blood disorders, or tumors compressing the pulmonary arteries.
Symptoms From Early to Advanced Stages
Pulmonary hypertension is notoriously difficult to catch early because its first symptoms overlap with dozens of less serious conditions. The cardinal symptom is breathlessness during physical activity that gradually worsens over months or years. You might also notice reduced exercise tolerance, chest tightness, heart palpitations, or lightheadedness during exertion. In the early stages, these symptoms appear only with activity and vanish at rest, which is why many people dismiss them or attribute them to being out of shape.
As the disease progresses and the right heart begins to fail, symptoms appear even at rest. Swelling in the ankles and legs develops as fluid accumulates. The veins in the neck may become visibly distended and pulsate. In advanced stages, people can experience fainting episodes, cold or bluish extremities, abdominal swelling from an enlarged liver, and a prolonged time for color to return when you press on a fingernail. Dizziness, pallor, and extreme fatigue become constant rather than occasional.
Who Gets Pulmonary Hypertension
Globally, roughly 192,000 people were living with pulmonary arterial hypertension (Group 1) as of 2021, with about 43,000 new cases diagnosed that year. Women are affected about 1.5 times more often than men. Prevalence and incidence peak in the 55 to 59 age range for both sexes, and the risk rises substantially after age 65.
Children under five face a particular danger: although PAH is rare in young children, mortality in that age group is disproportionately high, often because the condition is linked to congenital heart defects and the cardiopulmonary system hasn’t fully matured. Among adults, death rates climb with age and peak in the 80 to 84 age group.
Genetics play a measurable role, particularly in Group 1. Mutations in the BMPR2 gene are found in about 82% of people who have a family history of PAH. Even among people with no family history, roughly 17% carry a BMPR2 mutation. Overall, about 29% of PAH patients in large studies have an identifiable BMPR2 mutation, making it the most significant known genetic risk factor.
How It’s Diagnosed
Suspicion often starts with an echocardiogram, an ultrasound of the heart that can estimate pulmonary pressures and show whether the right ventricle is enlarged or struggling. But the definitive test is right heart catheterization. A thin catheter is inserted through a vein, typically in the neck or groin, and guided into the right side of the heart and pulmonary arteries. This procedure directly measures the pressures that define the condition.
The key numbers doctors look for: a mean pulmonary arterial pressure above 20 mmHg confirms pulmonary hypertension. To classify it as pulmonary arterial hypertension (Group 1) specifically, the wedge pressure, which reflects pressure backing up from the left side of the heart, must be 15 mmHg or lower, and pulmonary vascular resistance must exceed 3 Wood units. These distinctions matter because they determine which treatments will help.
Treatment by Type
Treatment differs dramatically depending on which group you fall into. For Group 2, the focus is on treating the underlying heart condition. For Group 3, managing the lung disease and supplemental oxygen take priority. Group 4 can sometimes be addressed surgically. But Group 1, pulmonary arterial hypertension, has an entire class of targeted drug therapies built around three biological pathways that go wrong in the disease.
The first pathway involves a substance called endothelin, a powerful blood vessel constrictor that’s overproduced in PAH. Medications that block endothelin receptors help relax the pulmonary arteries and slow the remodeling process. A second approach targets the nitric oxide pathway, which normally keeps blood vessels relaxed. Some medications prevent the breakdown of a chemical messenger that nitric oxide relies on, effectively amplifying the body’s own vessel-relaxing signals. A third class mimics prostacyclin, a natural compound that dilates blood vessels and prevents blood cells from clumping. These medications come in inhaled, oral, and intravenous forms, with the delivery method often reflecting disease severity.
A small subset of patients respond dramatically to calcium channel blockers, which are simpler, older medications. These patients are identified through a vasoreactivity test during their catheterization, where a short-acting dilator is given to see if the pulmonary arteries relax significantly. Most people with PAH don’t qualify, but for those who do, the response can be excellent.
Many patients end up on combination therapy, using drugs from two or even three of these pathways simultaneously. For the most advanced cases that don’t respond to medication, lung transplantation remains an option.
Living With Pulmonary Hypertension
Survival has improved considerably with modern therapies. Data from specialized centers show one-year survival rates around 96% and five-year survival around 87% for Group 1 PAH, a significant improvement over the pre-treatment era when median survival after diagnosis was measured in just a few years.
Supplemental oxygen is recommended when blood oxygen saturation drops to 90% or below, either at rest or during activity. For those who need it, the standard prescription is oxygen for at least 16 hours per day, with the flow rate adjusted to keep saturation above 90%. Exercise is no longer discouraged the way it once was. Supervised, moderate physical activity has become part of the management approach, though the intensity and type should be tailored to how advanced the disease is and how the right heart is functioning.
Because symptoms develop so gradually, diagnosis is often delayed by months or even years. People who experience unexplained, progressive breathlessness during activities they previously handled without difficulty, particularly if they have risk factors like connective tissue disease, a family history of PAH, or a history of blood clots, benefit from earlier evaluation rather than waiting for symptoms to become severe.